p57Kip2 is an essential regulator of vitamin D receptor-dependent mechanisms

Katsuhiko Takahashi; Hitoshi Amano; Tomohiko Urano; Minqi Li; Meiko Oki; Kazuhiro Aoki; Norio Amizuka; Keiichi I. Nakayama; Keiko Nakayama; Nobuyuki Udagawa; Nobuaki Higashi

doi:10.1371/journal.pone.0276838

Abstract

A cyclin-dependent kinase (CDK) inhibitor, p57^Kip2, is an important molecule involved in bone development; p57^Kip2-deficient (p57-/-) mice display neonatal lethality resulting from abnormal bone formation and cleft palate. The modulator 1α,25-dihydroxyvitamin D₃ (l,25-(OH)₂VD₃) has shown the potential to suppress the proliferation and induce the differentiation of normal and tumor cells. The current study assessed the role of p57^Kip2 in the 1,25-(OH)₂VD₃-regulated differentiation of osteoblasts because p57^Kip2 is associated with the vitamin D receptor (VDR). Additionally, 1,25-(OH)₂VD₃ treatment increased p57^KIP2 expression and induced the colocalization of p57^KIP2 with VDR in the osteoblast nucleus. Primary p57-/- osteoblasts exhibited higher proliferation rates with Cdk activation than p57+/+ cells. A lower level of nodule mineralization was observed in p57-/- osteoblasts than in p57+/+ cells. In p57+/+ osteoblasts, 1,25-(OH)₂VD₃ upregulated the p57^Kip2 and opn mRNA expression levels, while the opn expression levels were significantly decreased in p57-/- cells. The osteoclastogenesis assay performed using bone marrow cocultured with 1,25-(OH)₂VD₃-treated osteoblasts revealed a decreased efficiency of 1,25-(OH)₂VD₃-stimulated osteoclastogenesis in p57-/- cells. Based on these results, p57^Kip2 might function as a mediator of 1,25-(OH)₂VD₃ signaling, thereby enabling sufficient VDR activation for osteoblast maturation.

Citation: Takahashi K, Amano H, Urano T, Li M, Oki M, Aoki K, et al. (2023) p57^Kip2 is an essential regulator of vitamin D receptor-dependent mechanisms. PLoS ONE 18(2): e0276838. https://doi.org/10.1371/journal.pone.0276838

Editor: Chandi C. Mandal, Central University of Rajasthan, INDIA

Received: July 29, 2021; Accepted: October 14, 2022; Published: February 15, 2023

Copyright: © 2023 Takahashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript and its Supporting information files.

Funding: This work was supported by JSPS KAKENHI Grant Numbers JP15K07950 (KT), JP20K09474(HA), JP20K07789 (TU), JP19H01068 (KA), JP18H05215 (KIN), andJP19K07091 (NH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: NO authors have competing interests.

Introduction

Treatment with 1α,25-dihydroxyvitamin D₃ (l,25-(OH)₂D₃) suppresses the proliferation and induces the differentiation of osteoblastic cell lines. The induced growth inhibition was accompanied by a blockade of the transition from the G1 to S phase of the cell cycle [1]. We are interested in the regulatory role of l,25(OH)₂D₃ in cell growth and differentiation. The cyclin-dependent kinase inhibitor (CDKI) p57^Kip2 shares homology with the Cip/Kip family molecules p21^Cip1 and p27^Kip1 in the N-terminal domain (CDK inhibitory domain); additionally, CDKIs bind a variety of cyclin-CDK complexes and inhibit their kinase activities in vitro [2, 3]. Transfection of p57^Kip2 into Saos-2 osteosarcoma cells induced arrest at G1 phase through a mechanism that does not appear to require Rb or p53 [3]. Several reports have shown that SAOS2 cells were defective for p53 and Rb (Hinds et al. (1992), van der Heudel and Harlow [4, 5]). Decreased p57^Kip2 expression levels have been detected in several types of tumors [6–9]; consequently, p57^Kip2 might function as a tumor suppressor.

Mice deficient in the p57^Kip2 gene exhibit defective endochondral bone formation. Most p57^Kip2-deficient mice die shortly after birth as a result of severe cleft palate. In studies using mice lacking Cip/Kip family CDKIs (p21^Cip1, p27^Kip1 and p57^Kip2), only p57^Kip2-deficient mice exhibited developmental abnormalities, including several defects attributed to abnormal bone formation [10–12]. Based on these results, p57^Kip2 might function as a cellular mediator of bone formation.

Bone resorption by osteoclasts is an important event in calcium homeostasis and bone metabolism. The maturation of osteoblasts involves mineralization and the upregulation of osteoclastogenic genes, and 1,25-(OH)₂VD₃, which is the most active metabolite of vitamin D₃, is a hormone required for osteoblast function [13–17]. This hormone exerts a positive effect on bone mass when administered in vivo. Osteoblasts express nuclear vitamin D₃ receptors (VDRs) and show increased expression of osteopontin (opn) and rankl after treatment with 1,25-(OH)₂VD₃. Osteoblasts are considered the major target of 1,25-(OH)₂VD₃ in bone [15,18]. Through interactions with nuclear VDRs, 1,25-(OH)₂VD₃ inhibits osteoblastic cell proliferation and upregulates the expression of VDR-dependent genes, including opn [19] and rankl [20], which increase the functional activity of mature osteoblasts to induce osteoclastogenesis.

The current study assessed the role of p57^Kip2 in the 1,25-(OH)₂VD₃-regulated differentiation of osteoblasts because p57^Kip2, but not other Cip/Kip molecules, was associated with VDR. In osteoblasts, VDR-dependent genes, including opn and rankl, were upregulated by VD₃-VDR, and p57-/- osteoblasts did not show upregulation of these genes. Because significantly higher levels of an osteoclastogenesis inhibitor, osteoprotegerin, were detected in p57-/- osteoblasts than p57+/+ cells, p57^Kip2 may suppress osteoprotegerin (opg) expression in osteoblasts. Based on these results, we hypothesized that p57^Kip2 might be a mediator of 1,25-(OH)₂VD₃ signaling.

Materials and methods

Mice

Experimental animals carrying a targeted mutation in the p57^Kip2 loci were supplied by F. Hoffmann-La Roche, Ltd (Basel, Switzerland) [12]. The current study was approved by the Animal Use and Care Committee of Hoshi University. Mouse genotypes were determined by PCR. The p57^Kip2 locus is imprinted and expressed from the maternally derived allele. All experiments were conducted in accordance with the approval of the Hoshi University Animal Care and Use Committee (certificate number 20–070).

Histology and immunohistochemistry

Dissected tissues were fixed with 4% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4). For the histological analysis, fixed samples were demineralized for 2 days in 10% formic acid, dehydrated with ascending concentrations of ethanol, cleared in xylene and embedded in paraffin wax. Embedded samples were sectioned at 5 μm; each section was retrieved from the water bath. For tartrate-resistant acid phosphatase (TRAP) enzyme histochemistry, the sections were deparaffinized, followed by immersion in 50 ml of an aqueous solution containing 5 mg of naphthol AS-BI phosphate (Sigma, St. Louis, MO), 25 mg of red violet LB salt (Sigma) and 100 mM L-(+) tartaric acid (0.76 g; Sigma) diluted in 0.1 M sodium acetate buffer (pH 5.4) for 15 min at 37°C. For OPN immunohistochemistry, dewaxed sections were treated with 0.1% hydrogen peroxidase for 20 min to inhibit endogenous peroxidases; subsequently, dewaxed samples were pre-incubated with 1% bovine serum albumin in phosphate-buffered saline (pH 7.2; BSA-PBS) for 30 min at room temperature. Antisera against OPN (LSL Co., Tokyo, Japan) diluted 1:3000 were applied to the sections overnight at 4°C, after which the specimens were incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Chemicon International Inc., Temecula, CA). Immunoreactions were visualized with diaminobenzidine as a substrate prior to observation under a light microscope. These sections were lightly counterstained with methyl green.

Preparation of primary mouse osteoblasts

Primary cultures of calvarial osteoblasts were prepared using the sequential collagenase/dispase digestion method [21]. Briefly, calvaria were removed from newborn offspring derived from p57+/- males and p57+/- females; the neonates were denuded of soft tissue and digested with 1 mg/ml collagenase and 2 mg/ml dispase for 15 min at 37°C in PBS with gentle agitation. The procedure was performed twice; cells from the second digestion were harvested and grown to confluence in α-MEM supplemented with 1% penicillin-streptomycin (Wako Pure Chemicals, Osaka, Japan) and 10% FCS.

Immunoblot analysis

Cells were plated in 6-well plastic dishes and cultured with α-MEM containing 10% FCS, 5 mM β-glycerophosphate, 50 mg/ml ascorbic acid and antibiotics. The cells were treated with 1,25-(OH)₂VD₃ (10 nM) for 24 h prior to collection for protein assays. Cells were rinsed twice with ice-cold phosphate-buffered saline and lysed with 180 μl of Nonidet P-40 lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10 mM NaF, 5 mM EDTA, 5 mM EGTA, 2 mM sodium vanadate, 0.5% sodium deoxycholate, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin and 0.1% Nonidet P-40]; subsequently, the lysates were cleared by centrifugation at 15,000 × g for 5 min at 4°C. For immunoblot analyses, samples were separated on 9 or 12.5% SDS-PAGE gels. Immunoblotting was performed with an enhanced chemiluminescence detection system (GE Healthcare Life Sciences, Uppsala, Sweden). Anti-VDR and anti-β-Actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). A rabbit antibody against p57^Kip2 was raised against the peptides corresponding to the C-terminus of the p57^Kip2 protein.

Immunoprecipitation for the detection of the endogenous p57^Kip2-VDR complex

Cells were plated in 60-mm plastic dishes and cultured with α-MEM containing 10% FCS, 5 mM β-glycerophosphate, 50 mg/ml ascorbic acid and antibiotics. The cells were treated with 1,25-(OH)₂VD₃ (10 nM) for 24 h prior to collection for protein assays. Cells were rinsed twice with ice-cold phosphate-buffered saline and lysed with 500 μl of RIPA buffer (1 mM sodium vanadate, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM phenylmethylsulfonyl fluoride and 2 mg/ml aprotinin in phosphate-buffered saline); subsequently, the whole lysates were cleared by centrifugation at 15,000 × g for 5 min at 4°C. For VDR immunoprecipitation, the lysates (200 μg protein) were mixed with anti-VDR antibodies (Santa Cruz, CA). The immunocomplexes were precipitated with Protein A/G-Sepharose beads (GE Healthcare Life Sciences); subsequently, the pellets were washed six times with ice-cold RIPA buffer. The precipitates were separated on 9% SDS-PAGE gels. Immunoblotting for the detection of both p57^Kip2 and VDR was performed with an enhanced chemiluminescence detection system (GE Healthcare Life Sciences, Uppsala, Sweden). Anti-p57^Kip2 and anti-VDR antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Immunofluorescence staining.

Primary mouse osteoblasts were treated with 10 nM 1,25(OH)-VD₃ for 24 h. The cells were fixed with paraformaldehyde and incubated with the following primary antibodies: mouse anti-VDR (D-6: Santa Cruz Biotechnology) and rabbit anti-p57^Kip2 (EP2515Y, Abcam). After washing, the cells were incubated with the following secondary antibodies: Alexa Fluor 647-goat anti-mouse IgG and Alexa Fluor 488-goat anti-rabbit IgG (Jackson Immuno Reasearch). The cells were mounted with mounting medium containing DAPI to label the nuclei. Stained cells were detected by confocal microscopy (FV1200, Olympus); blue staining indicated DAPI-stained nuclei, red staining indicated VDR, and green staining indicated p57^Kip2. The scale bar represents 100 μm.

Nodule mineralization

Osteoblasts were plated in 12-well multiplates at a density of 2.5 × 10⁴ cells/well and grown to confluence for 10 days. Media were then replaced with mineralizing media (α-MEM supplemented with antibiotics, 10% FCS, 10 μM β-glycerophosphate, 100 μg/ml ascorbic acid and 100 nM dexamethasone). Following an additional 3 weeks of culture [22], mineralization was detected with the von Kossa staining method. The von Kossa-stained area was measured with the application MetaMorph.

Quantitative RT-PCR

The expression levels of the murine p57^Kip2 and opn mRNAs in mouse primary osteoblasts were evaluated with quantitative RT-PCR (qRT-PCR) using a Prism 7000 System (Applied Biosystems, Foster City, CA) and SYBR Green I fluorescence as previously described [23–25]. The expression levels of the human p57^Kip2 and opn mRNAs in SaOS2 cells were also assessed using qRT-PCR. The cDNA templates were synthesized from 1 μg of total RNA using the First Strand cDNA Synthesis Kit (GE Healthcare Life Sciences). The relative levels of the mouse and human p57^Kip2 and opn mRNAs, which were normalized to the reference gene hypoxanthine-guanine phosphoribosyl transferase (hprt1), were determined using the comparative Ct (cycles at threshold fluorescence) method. All experiments were independently repeated three times, i.e., each experiment was performed in triplicate. The sequences of the PCR primers are as follows: mouse p57^Kip2 (forward 5’-AACCGCTGGGACTTCAACTTC-3’, reverse 5’-AGACTCGCTGTCCACCTCCAT-3’), mouse opn (forward 5’-CCCTCGATGTCATCCCTGTT-3’, reverse 5’-CTGCCCTTTCCGTTGTTGTC-3’), mouse hprt1 (forward 5’-TGGGAGGCCATCACATTGT-3’, reverse 5’-AGCAGGTCAGCAAAGAACTTATAGC-3’), mouse rankl (forward 5’-CCAGCATCAAAATCCCAAGTTC-3’, reverse 5’-TGCCCGACCAGTTTTTCG-3’), mouse opg (forward 5’-GCCTGGGACCAAAGTGAATG-3’, reverse 5’-CTTGTGAGCTGTGTCTCCGTTT-3’), human p57^KIP2 (forward 5’-AGTCCCTCGACGGCCTCGAG-3’, reverse 5’-CGGGACCGGGACACTAGGCA-3’), and human opn (forward 5’-ATGAGCATTCCGATGTGATTG-3’, reverse 5’-TGTGGAATTCACGGCTGA-3’).

Constructs and transfection

Expression plasmids for amino terminally HA-tagged VDR (HA-VDR) were constructed by ligating the cDNA fragments into the FLAG-pcDNA3.1(-) vector. For transfection, the human osteosarcoma cell line SaOS2 and its tetracycline (tet)-off p57^Kip2 stable transfectant were used. Cells (5 × 10⁵) were grown in 100-mm culture dishes; Lipofectamine (Invitrogen) was employed according to the manufacturer’s instructions. Cells were harvested or analyzed after 48 h. Immunoblotting and immunoprecipitation were performed as described previously [26]. For immunoprecipitation, the cell lysates were mixed with anti-FLAG M2 affinity gel (Sigma); FLAG-tagged proteins were eluted with the 3 × FLAG peptide after washing. The eluate was subjected to immunodetection utilizing anti-FLAG, anti-VDR and anti-p57^Kip2 antibodies.

Statistical analysis

All data were analyzed with Student’s t-test and two-way ANOVA. Differences were considered statistically significant when p < 0.01.

Results

The VD₃-dependent interaction between VDR and p57^Kip2

We hypothesized that the 1,25-(OH)₂VD₃ (VD₃) activity in osteoblasts might depend on the p57^Kip2 protein. In the immunoprecipitation analysis of the primary mouse osteoblasts, p57^Kip2 was detected in the complex precipitated with anti-VDR antibodies in the VD₃-stimulated osteoblasts (Fig 1A). VD₃ stimuli also induced the colocalization of p57^Kip2 with VDR in the nuclei of the primary mouse osteoblasts (Fig 1B).

Download:

Fig 1. The association of p57^Kip2 with VDR is dependent on 1,25-(OH)₂VD₃.

A. The association of p57^Kip2 with VDR is dependent on 1,25-(OH)₂VD₃ in primary p57+/+ osteoblasts. Top photo: immunoprecipitation (IP) was performed with an anti-VDR antibody, and immunoblotting (IB) was conducted with an anti-p57^Kip2 antibody. Bottom: immunoprecipitation and immunoblotting were performed with an anti-VDR antibody. B. Immunofluorescence staining of primary mouse osteoblasts that were treated with 10 nM 1,25-(OH)₂VD₃ for 24 h. Blue indicates DAPI-stained nuclei, red indicates VDR, and green indicates p57^Kip2. The scale bar represents 100 μm.

https://doi.org/10.1371/journal.pone.0276838.g001

p57^Kip2 enhances the transcriptional activities of VDR

Next, we used SaOS2 cells characterized by tet-off regulation of p57^Kip2 to assess the effects of p57^Kip2 on VDR activation. In humans and rodents, the expression of opn transcripts depends on the formation of the 1,25-(OH)₂VD₃-VDR complex at the VDR response element (VDRE) [27, 28]. In the absence of tet, the expression of both the p57^Kip2 and opn mRNAs was upregulated (Fig 2A and 2B). In the presence of tet, p57^Kip2 transcripts were also downregulated by the tet-off system (Fig 2A). Because opn transcripts were simultaneously decreased in the presence of tet, p57^Kip2 expression increased the levels of the opn mRNA (Fig 2B). We performed a luciferase assay employing a reporter plasmid with the opn 5’ flanking region-luciferase cDNA to investigate the role of p57^Kip2 in the activation of the VDRE. Following cotransfection of the reporter plasmid and VDR expression plasmids into SaOS2 tet-off p57^Kip2-stable cells, luciferase activity increased by two-fold upon the addition of 1,25-(OH)₂VD₃. Our SaOS2 tet-off p57^Kip2-stable cells may have expressed p57^Kip2 at sufficient levels to activate the opn 5’ flanking region when the cells were cultured in medium lacking tet. The p57^Kip2-on cells might have expressed p57^Kip2 at excessively high levels that were unable to increase the activity of the opn 5’ flanking region through VDR expression, and the opn 5’ flanking region was strongly activated by 1,25-(OH)₂VD₃ (Fig 2D). Under the tet-off condition (basal levels of p57^Kip2), VDR expression was sufficient for opn promoter activation by 1,25-(OH)₂VD₃; furthermore, the induction of both VDR and p57^Kip2 expression increased the activation of the promoter after the 1,25-(OH)₂VD₃ treatment (Fig 2C). Thus, p57^Kip2 activated the opn 5’ region, and the coexistence of p57^Kip2 and VDR increased the 1,25-(OH)₂VD₃-induced activation of opn expression. Osteogenic homeostasis mediated by 1,25-(OH)₂VD₃ might be sufficient in osteoblasts expressing both p57^Kip2 and VDR.

Download:

Fig 2. p57^Kip2 Upregulates the VD₃-dependent expression of opn transcripts.

Expression levels of both p57^Kip2 (A) and opn (B) depended on the presence of tetracycline in the SaOS2 tet-off p57^Kip2 transfectant. An asterisk indicates statistical significance: #, p < 0.01. (C) The activity of the opn promoter was estimated in SaOS2 tet-off p57^Kip2-transfected cells. In the SaOS2 tet-off p57^Kip2 transfectant, p57^Kip2 expression (- tetracycline) upregulated opn promoter activity independently of 1,25-(OH)₂VD₃. Under equal transfection conditions, an asterisk indicates a statistically significant difference between 0.1% ethanol and 1,25-(OH)₂VD₃: *, p < 0.01. Under equal culture conditions, a # symbol indicates a statistically significant difference among transfection conditions: #, p < 0.01. The open columns represent the vehicle (0.1% ethanol: EtOH), whereas the closed columns represent 10 nM 1,25-(OH)₂VD₃.

https://doi.org/10.1371/journal.pone.0276838.g002

Effects of the ablation of p57^Kip2 in primary cultured osteoblasts

We prepared primary calvarial osteoblasts harvested from neonates to examine the role of p57^Kip2 in osteoblast maturation in detail. The primary p57-/- osteoblasts displayed a higher proliferation rate than wild-type (p57+/+) cells (S Fig 1 in S1 File). The continuous induction of differentiation in the confluent osteoblasts was observed in an in vitro culture for three weeks. After extended culture, p57-/- osteoblasts exhibited lower levels of mineralization than p57+/+ cells. The levels of p57^Kip2 transcripts and proteins in cultured primary mouse osteoblasts were assessed after treatment with 1,25-(OH)₂VD₃. The qRT-PCR analysis revealed the upregulation of the p57^Kip2 transcript in 1,25-(OH)₂VD₃-treated mouse osteoblasts (Fig 3A). Concomitant with the increase in the levels of p57^Kip2 transcripts, substantially increased levels of the p57^Kip2 protein were detected using immunoblotting (Fig 3B). These findings were consistent with a previous report noting the stabilization of p57^Kip2 protein in rat osteoblasts in the presence of 1,25-(OH)₂VD₃ [29]. Subsequently, we hypothesized that 1,25-(OH)₂VD₃ activity in osteoblasts might depend on the levels of the p57^Kip2 protein. An analysis of opn mRNA levels in p57+/+ osteoblasts in the early phase of mineralization revealed an upregulation of opn transcripts, which was increased two-fold by 1,25-(OH)₂VD₃. In p57-/- cells, the induction of differentiation did not lead to increased opn expression; however, the 1,25-(OH)₂VD₃ treatment induced opn expression (Fig 3C). Thus, the expression of opn transcripts in osteoblasts might depend on VDR and p57^Kip2. Nodule mineralization was observed during the extended culture of both p57-/- and p57+/+ cells; furthermore, the mineralized nodules in p57-/- cells were significantly smaller than those in p57+/+ cells (Fig 3D). Additionally, the area of the mineralized nodules was reduced by approximately 30% (Fig 3D and 3E). Primary p57+/+ osteoblasts expressed opn mRNA at higher levels than p57-/- cells, and the differences were more obvious in confluent osteoblasts stimulated with mineralization medium (Fig 3F). Immunohistochemistry findings demonstrated lower levels of Opn-expressing osteoblasts in the bone medulla of p57-/- neonates than in p57+/+ neonates (S Fig 2 in S1 File). Based on these results, we hypothesized that p57^Kip2 might be necessary to ensure the sufficient bioactivity of 1,25-(OH)₂VD₃ during osteoblastic maturation.

Download:

Fig 3. Effects of the ablation of p57^Kip2 on primary cultured osteoblasts.

(A) Results of the quantitative RT-PCR analysis of p57^Kip2 transcripts. The results were normalized to hprt levels. An asterisk indicates a statistically significant difference: *, p < 0.01. (B) Immunoblot showing the levels of p57^Kip2. In A and B, cells were treated with the vehicle (0.1% ethanol: Cont.) or 10 nM 1,25-(OH)₂VD₃ (VD3) for 24 h. (C) The effect of 10 nM 1,25-(OH)₂VD₃ on the expression of the osteopontin mRNA was analyzed using quantitative RT-PCR. The results were normalized to the hprt mRNA. Under equal conditions, an asterisk indicates a statistically significant difference between 0.1% ethanol and 1,25-(OH)₂VD₃: *, p < 0.01. The # symbol indicates a statistically significant difference between p57+/+ and p57-/- cells: #, p < 0.01. (D) Images of von Kossa staining of nodule mineralization in extended-culture osteoblastic cells. Primary osteoblasts were plated in 12-well multiplates, grown to confluence and incubated for 21 days with ascorbic acid, β-glycerophosphate and dexamethasone. (D) Photo of von Kossa-stained cells. (E) Graph of the analysis of the cells shown in (D) [mineralization area (%)]. An asterisk indicates a statistically significant difference: *, p < 0.01. (F) The expression of the osteopontin mRNA in p57+/+ and p57-/- osteoblasts was analyzed using quantitative RT-PCR. Cells grown to 70% confluence were “growing cells”, and mineralized confluent cells were “differentiated cells”. The results were normalized to the hprt mRNA. The # symbol indicates a statistically significant difference between p57+/+ and p57-/- cells: #, p < 0.01. The $ symbol indicates a statistically significant difference between growing and differentiated cells: $, p < 0.01.

https://doi.org/10.1371/journal.pone.0276838.g003

p57-/- osteoblasts exhibit defects in osteoclastogenesis

We hypothesized that p57^Kip2 might play a role in the 1,25-(OH)₂VD₃-induced osteoclastogenesis of osteoblasts. We cocultured 1,25-(OH)₂VD₃-treated osteoblasts with bone marrow cells to identify the roles of p57^Kip2 in the osteoclastogenic activity of osteoblasts. Notably, 1,25-(OH)₂VD₃ stimulated osteoclastogenesis in p57+/+ primary osteoblasts more effectively than in p57-/- osteoblasts (S Fig 3 in S1 File). Based on these findings, p57^Kip2 might be necessary to maintain proper mineralization and p57^Kip2 might promote VD₃ signaling. Receptor activator of NF-kappa B ligand (Rankl) is a membrane-bound signal transducer responsible for the differentiation and maintenance of osteoclasts. In p57+/+ osteoblasts, rankl transcripts were upregulated 4.7-fold after 1,25-(OH)₂VD₃-treatment (72 h) (Fig 4A). Opg, also known as an osteoclastogenesis inhibitory factor, functions as a decoy receptor for Rank to obstruct Rankl-Rank signaling and inhibit osteoclastogenesis. The expression of opg transcripts was significantly increased in p57-/- osteoblasts (Fig 4B). Rankl expression might depend on p57^Kip2 to some extent, and opg expression might be suppressed by p57^Kip2. Thus, the defects in p57-/- osteoblasts might result from disturbances in rankl and opg expression levels. Additionally, 1,25-(OH)₂VD₃ upregulated rankl expression by 4.7-fold in p57+/+ cells and 1.4-fold in p57-/- cells (Fig 4A). The expression of rankl is regulated by VD₃-VDR activation [30–32]. The p57^Kip2 deficiency reduced cellular responses to 1,25-(OH)₂VD₃. In contrast to rankl, opg expression was not altered by 1,25-(OH)₂VD₃ in both p57+/+ and p57-/- cells (Fig 4B). The ratio of rankl/opg expression may be useful as an indicator of the osteoclastogenic activity of osteoblasts [32, 33]. As shown in Fig 4D, p57+/+ cells displayed higher rankl/opg ratios than p57-/- cells. Treatment with 1,25-(OH)₂VD₃ significantly increased the ratio in p57+/+ cells (Fig 4C). From these results, we concluded that the ablation of p57^Kip2 upregulated opg, suppressed 1,25-(OH)₂VD₃-dependent rankl expression, and resulted in defects in osteoclastogenic activities in osteoblasts.

Download:

Fig 4. VD₃-induced rankl expression in osteoblasts depended on p57^Kip2.

(A) Quantitative RT-PCR analysis of the levels of the rankl mRNA in osteoblasts treated with 0.1% ethanol (-) or 10 nM 1,25-(OH)₂VD₃ (+) for 72 h. Levels of the rankl mRNA were normalized to the mRNA levels of the constitutive gene hprt1. (B) Quantitative RT-PCR analysis of the expression of the opg mRNA in osteoblasts treated with 0.1% ethanol (-) or 10 nM 1,25-(OH)₂VD₃ (+) for 72 h. Levels of the opg mRNA were normalized to the mRNA levels of the constitutive gene hprt1. (C) The relative ratio of the rankl mRNA/opg mRNA was calculated and compared between p57+/+ and p57-/- osteoblasts. In the graphs, relative levels in p57+/+ cells were estimated. The # symbol indicates a statistically significant difference between p57+/+ and p57-/- cells: #, p < 0.01. The asterisk indicates a statistically significant difference between 0.1% ethanol (-) and 10 nM 1,25-(OH)₂VD₃ (+): *, p < 0.01.

https://doi.org/10.1371/journal.pone.0276838.g004

Discussion

As shown in the current study, p57^Kip2 specifically interacted with VDR and was required for osteoclastogenesis activities in osteoblasts. Studies using knockout mice indicated that p57^Kip2 functions mainly as a CDKI in mouse osteoblasts, because the lack of genes encoding other Cip/Kip family molecules, including both p21^Cip1 and p27^Kip1, did not result in abnormal bone formation, which was observed in p57-/- mice [11–13].

The degradation of p57^Kip2 via the proteasome pathway inhibits osteoblast maturation [34–37]. Thus, the expression of p57^Kip2 is necessary for osteoblast maturation. Following the evaluation of a novel ubiquitin ligase, FBL12, which is involved in TGF-1β-induced degradation of p57^Kip2, Kim et al. [36] noted that p57^Kip2 overexpression promotes the differentiation of primary osteoblasts. VD₃ increased p57^Kip2 levels in mouse osteoblasts. We revealed the VD₃-dependent upregulation of p57^Kip2 in mouse osteoblasts, and an increase in levels of the p57^Kip2 protein might also be associated with an increase its stabilization.

In our study, VDR was specifically associated with the CDKI domain of p57^Kip2. Cip/Kip molecules contain a characteristic CDKI domain (Fig 5). The p57^Kip2 CDKI domain contains the specific hydrophilic AELNAEDQN peptide and hydrophobic PLRGPGRLQ peptide. The 3D structure of p57^Kip2 has not yet been reported, but these p57^Kip2-specific peptides might be involved in the interaction with VDR. As shown in the study by Valcheva et al. [38], G0-synchronized primary VDR-deficient vascular smooth muscle cells express p57^Kip2 at higher levels than wild-type cells. These findings prompted us to investigate the regulation of p57^Kip2 levels by the VDR complex. The LBD of VDR was responsible for the interaction with p57^Kip2. This peptide of VDR contains the common LBD for other nuclear receptors, including PXR, LXR, FXR THR and RXR. According to our results, p57^Kip2 might interact with various nuclear receptors to regulate their activity. Joseph B et al. reported that p57Kip2 cooperated with Nurr1, the same nuclear receptor as VDR, and activated transcriptional activity at its transcription factor binding site (NBRE). Therefore, we investigated whether p57Kip2 also cooperated with VDR to activate transcriptional activity at the transcription factor binding site (VDRE) [39]. The coexistence of p57 and VDR facilitated 1,25-(OH)₂VD₃-dependent VDR activation, and p57 functioned as a cofactor of VDR.

Download:

Fig 5. CDKI domains of Cip/Kip family molecules.

Characteristic CDKI domains were compared among mouse (Mus musculus) p57^Kip2, human (Homo sapiens) p57^Kip2, p27^Kip1 and p21^Cip1. Identical amino acid residues in 3 of 4 peptides are enclosed with a red line. A blue line surrounds p57^Kip2-specific peptides, which were shared by mouse and human sequences.

https://doi.org/10.1371/journal.pone.0276838.g005

As shown in Fig 4, p57^Kip2 regulated opg expression in mouse osteoblasts, in contrast to opn and rankl. The osteoclastogenic activities of osteoblasts depend on Rankl and Opg. Rankl is a membrane-bound signal transducer responsible for the differentiation and maintenance of osteoclasts; in addition, Rankl promotes osteoclast differentiation. In conjunction with the differences in rankl mRNA levels, p57-/- osteoblasts were inferior to p57+/+ cells in terms of osteoclast induction activity. As shown in our current study, p57^Kip2 regulated opg expression, and the ablation of p57^Kip2 significantly upregulated the expression of the opg mRNA. Opg is the decoy receptor for Rankl to prevent osteoclastogenesis. Defects in osteoclastogenesis due to a lack of p57^Kip2 might result from both an increase in opg expression and the downregulation of rankl. Several studies have described the regulation of opg expression in osteoclastogenesis [20, 27, 40–42], but no information is available on opg downregulation. When opg was discovered by Yasuda et al. [41], most researchers believed that opg expression was vitamin D-dependent. However, Nakamichi et al. [43] reported that rankl mRNA expression was VDR dependent but opg expression in osteoblast-specific KO mice did not change after treatment with 1, 25 vitamin D3. These results suggested that opg expression might not be VDR dependent. Recently, cancer cells were shown to release more Opg than normal cells [44–48]. Because p57^Kip2 is a tumor suppressor protein, p57^Kip2-deficient cancer cells may express and release Opg.

The levels of the opn mRNA in osteoblasts are consistent with the in vivo osteomalacia-like phenotype; however, in vitro, p57-/- osteoblasts cultured with maturation medium produced fewer mineralized nodules than p57+/+ cells. The expression of the opn mRNA was also upregulated by 1,25-(OH)₂VD₃-VDR activity, similar to rankl. Kitazawa et al. [30–32] previously reported that 1,25-(OH)₂VD₃ enhances osteoclastogenesis via the transactivation of the rankl gene in osteoblasts through the VDRE in both humans and mice. Urano et al. [29] observed the upregulation of p57^Kip2 transcripts and increased levels of the p57^Kip2 protein in rat osteoblasts (p57+/+) cultured in the presence of 1,25-(OH)₂VD₃. We expected that sufficient VDR activation by 1,25-(OH)₂VD₃ activity might be mediated by p57^Kip2 during osteoblast maturation. An assessment of the SaOS2 tet-off p57^Kip2 stable cell line yielded data consistent with our expectations, at least in terms of the activation of the opn promoter containing the VDRE. Of course, our results might be partially attributed to the interaction of p57^Kip2 and VDR in osteoblasts and might depend on the other pathway via CDK activation.

In the present study p57^Kip2 formed complexes with VDR and function as a cell cycle regulator and a mediator of the 1,25-(OH)₂VD₃-induced transcriptional activation of osteoblast genes in mineralizing osteoblastic cells. These data identified possible roles for p57^Kip2 in regulating osteoblast differentiation and bone metabolism.

Supporting information

S1 Raw images.

https://doi.org/10.1371/journal.pone.0276838.s001

(PDF)

S1 File.

https://doi.org/10.1371/journal.pone.0276838.s002

(PPTX)

Acknowledgments

We would like to thank T Usui for providing the SaOS2 tet-off p57^Kip2 cells. We would also like to thank T Tomuro, A Nara, Y Takahashi, R Oikawa, Dr. A Karakawa, Dr. Y Nakamichi, Prof. S Inoue, Prof. H Itabe and Prof. M Tomita for their support of this study. In addition, we wish to thank Prof. E Abe for critically reading the manuscript.

References

1. Eelen G, Verlinden L, Van Camp M, Van Hummelen P, Marchal K, De Moor B, et al. The effects of 1α,25-dihydroxyvitamin D₃ on the expression of DNA replication genes. J Bone Miner Res. 2004;19: 133–146.
- View Article
- Google Scholar
2. Lee MH, Reynisdottir I, Massague J. Cloning of p57^KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995;9: 639–649.
- View Article
- Google Scholar
3. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, et al. p57^KIP2, a structurally distinct member of the p21^CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995;9: 650–662.
- View Article
- Google Scholar
4. Hinds P.W., Mittnacht S., Dulic V., Arnold A., Reed S.I., and Weinberg R.A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70: 993–1006. pmid:1388095
- View Article
- PubMed/NCBI
- Google Scholar
5. van der Heuvel S. and Harlow E. Distinct roles for cyclin dependent kinases in cell cycle control. Science, 1993; 26: 2050–2054.
- View Article
- Google Scholar
6. Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, Gorgoulis VG. p57^KIP2: "Kip"ing the cell under control. Mol Cancer Res. 2009;7: 1902–1919.
- View Article
- Google Scholar
7. Borriello A, Caldarelli I, Bencivenga D, Criscuolo M, Cucciolla V, Tramontano A, et al. p57^Kip2 and cancer: time for a critical appraisal. Mol Cancer Res. 2011;9: 1269–1284.
- View Article
- Google Scholar
8. Kavanagh E, Joseph B. The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta. 2011;1816: 50–56. pmid:21447370
- View Article
- PubMed/NCBI
- Google Scholar
9. Jayapal SR, Kaldis P. p57^Kip2 regulates T-cell development and lymphoma. Blood. 2014;123: 3370–3371.
- View Article
- Google Scholar
10. Zhang P, Liégeois NJ, Wong C, Finegold M, Hou H, Thompson JC, et al. Altered cell differentiation and proliferation in mice lacking p57^KIP2 indicates a role in Beckwith–Wiedemann syndrome. Nature. 1997;387: 151–158.
- View Article
- Google Scholar
11. Yan Y, Frisen J, Lee MH, Massague J, Barbacid M. Ablation of the CDK inhibitor p57^Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997;11: 973–983.
- View Article
- Google Scholar
12. Takahashi K, Nakayama K, Nakayama K. Mice lacking a CDK inhibitor, p57^Kip2, exhibit skeletal abnormalities and growth retardation. J Biochem. 2000;127: 73–83.
- View Article
- Google Scholar
13. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Investig. 1979;64: 729–736. pmid:468987
- View Article
- PubMed/NCBI
- Google Scholar
14. Lian JB, Stein GS. Transcriptional control of vitamin D-regulated proteins. J Cell Biochem. 1992;49: 37–45. pmid:1644852
- View Article
- PubMed/NCBI
- Google Scholar
15. Kato S, Suzawa M, Takada I, Takeyama K, Yanagizawa J, Fujiki R, et al. The function of nuclear receptors in bone tissues. J Bone Miner Metab. 2003;21: 323–336. pmid:14586788
- View Article
- PubMed/NCBI
- Google Scholar
16. Suda T, Ueno Y, Fujii K, Shinki T. Vitamin D and bone. J Cell Biochem. 2003;88: 259–266. pmid:12520524
- View Article
- PubMed/NCBI
- Google Scholar
17. Meyer MB, Benkusky NA, Lee C-H, Pike JW. Genomic determinants of gene regulation by 1,25-dihydroxyvitamin D₃ during osteoblast-lineage cell differentiation. J Biol Chem. 2014;289: 19539–19554.
- View Article
- Google Scholar
18. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol. 1997;154: S57–SS73. pmid:9379138
- View Article
- PubMed/NCBI
- Google Scholar
19. Noda M, Vogel RL, Craig AM, Prahl J, DeLuca HF, Denhardt DT. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D₃ receptor and 1,25-dihydroxyvitamin D₃ enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proc Natl Acad Sci U S A. 1990;87: 9995–9999.
- View Article
- Google Scholar
20. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95: 3597–3602. pmid:9520411
- View Article
- PubMed/NCBI
- Google Scholar
21. McKee MD, Nanci A. Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. Connect Tissue Res. 1996;35: 197–205. pmid:9084658
- View Article
- PubMed/NCBI
- Google Scholar
22. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000; 151: 311–320. pmid:11038178
- View Article
- PubMed/NCBI
- Google Scholar
23. Urano T, Narusawa K, Shiraki M, Usui T, Sasaki N, Hosoi T, et al. Association of a single nucleotide polymorphism in the WISP1 gene with spinal osteoarthritis in postmenopausal Japanese women. J Bone Miner Metab. 2007;25: 253–258. pmid:17593496
- View Article
- PubMed/NCBI
- Google Scholar
24. Urano T, Usui T, Takeda S, Ikeda K, Okada A, Ishida Y, et al. TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase. Biochem Biophys Res Commun. 2009;383: 263–268. pmid:19358823
- View Article
- PubMed/NCBI
- Google Scholar
25. Urano T, Shiraki M, Yagi H, Ito M, Sasaki N, Sato M, et al. GPR98/Gpr98 gene is involved in the regulation of human and mouse bone mineral density. J Clin Endocrinol Metab 2012; 97: E565–574. pmid:22419726
- View Article
- PubMed/NCBI
- Google Scholar
26. Hofbauer LC, Heufelder AE. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur J Endocrinol. 1998;139: 152–154. pmid:9724069
- View Article
- PubMed/NCBI
- Google Scholar
27. Koszewski NJ, Reinhardt TA, Horst RL. Vitamin D receptor interactions with the murine osteopontin response element. J Steroid Biochem Mol Biol. 1996;59: 377–388. pmid:9010343
- View Article
- PubMed/NCBI
- Google Scholar
28. Staal A, van Wijnen AJ, Birkenhäger JC, Pols HA, Prahl J, DeLuca H, et al. Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol. 1996;10: 1444–1456. pmid:8923469
- View Article
- PubMed/NCBI
- Google Scholar
29. Urano T, Hosoi T, Shiraki M, Toyoshima H, Ouchi Y, Inoue S. Possible involvement of the p57^Kip2 gene in bone metabolism. Biochem Biophys Res Commun. 2000;269: 422–426.
- View Article
- Google Scholar
30. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R. Vitamin D₃ supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem. 2003;89: 771–777.
- View Article
- Google Scholar
31. Kitazawa R, Kitazawa S, Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim Biophys Acta. 1999;1445: 134–141. pmid:10209265
- View Article
- PubMed/NCBI
- Google Scholar
32. Kitazawa R, Kitazawa S. Vitamin D₃ augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun. 2002;290: 650–655.
- View Article
- Google Scholar
33. Thomas GP, Baker SU, Eisman JA, Gardiner EM. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol. 2001;170: 451–460. pmid:11479141
- View Article
- PubMed/NCBI
- Google Scholar
34. Urano T, Yashiroda H, Muraoka M, Tanaka K, Hosoi T, Inoue S, et al. p57^Kip2 is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor β1. J Biol Chem. 1999;274: 12197–12200.
- View Article
- Google Scholar
35. Nishimori S, Tanaka Y, Chiba T, Fujii M, Imamura T, Miyazono K, et al. Smad-mediated transcription is required for transforming growth factor-β1-induced p57^Kip2 proteolysis in osteoblastic cells. J Biol Chem. 2001;276: 10700–10705.
- View Article
- Google Scholar
36. Kim M, Nakamoto T, Nishimori S, Tanaka K, Chiba T. A new ubiquitin ligase involved in p57^KIP2 proteolysis regulates osteoblast cell differentiation. EMBO Rep. 2008;9: 878–884.
- View Article
- Google Scholar
37. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, et al. Degradation of p57^Kip2 mediated by SCF^Skp2-dependent ubiquitylation. Proc Natl Acad Sci U S A. 2003;100: 10231–10236.
- View Article
- Google Scholar
38. Valcheva P, Cardus A, Panizo S, Parisi E, Bozic M, Lopez Novoa JM, et al. Lack of vitamin D receptor causes stress-induced premature senescence in vascular smooth muscle cells through enhanced local angiotensin-II signals. Atherosclerosis. 2014;235: 247–255. pmid:24880896
- View Article
- PubMed/NCBI
- Google Scholar
39. Joseph B, Wallén-Mackenzie A, Benoit G, Murata T, Joodmardi E, Okret S, et al. p57(Kip2) cooperates with Nurr1 in developing dopamine cells. Proc Natl Acad Sci U S A. 2003; 100: p15619–15624. pmid:14671317
- View Article
- PubMed/NCBI
- Google Scholar
40. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998;247: 610–615. pmid:9647741
- View Article
- PubMed/NCBI
- Google Scholar
41. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329–1337. pmid:9492069
- View Article
- PubMed/NCBI
- Google Scholar
42. Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K, et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun. 1998;251: 796–801. pmid:9790989
- View Article
- PubMed/NCBI
- Google Scholar
43. Nakamichi Y, Udagawa N, Horibe K, Mizoguchi T, Yamamoto Y, Nakamura T, et al. VDR in Osteoblast-Lineage Cells Primarily Mediates Vitamin D Treatment-Induced Increase in Bone Mass by Suppressing Bone Resorption. J Bone Miner Res. 2017; 32:1297–1308. pmid:28177161
- View Article
- PubMed/NCBI
- Google Scholar
44. Weichhaus M, Segaran P, Renaud A, Geerts D, Connelly L. Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis. Cancer Med. 2014;3: 1112–1125. pmid:24976340
- View Article
- PubMed/NCBI
- Google Scholar
45. Goswami S, Sharma-Walia N. Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer. 2015;15: 935. pmid:26608463
- View Article
- PubMed/NCBI
- Google Scholar
46. Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 2006;66: 3620–3628. pmid:16585187
- View Article
- PubMed/NCBI
- Google Scholar
47. Pettersen I, Bakkelund W, Smedsrød B, Sveinbjørnsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005;25: 3809–3816. pmid:16309167
- View Article
- PubMed/NCBI
- Google Scholar
48. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TEM, Blair JM, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 2005;65: 1710–1718. pmid:15753366
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Eelen G, Verlinden L, Van Camp M, Van Hummelen P, Marchal K, De Moor B, et al. The effects of 1α,25-dihydroxyvitamin D₃ on the expression of DNA replication genes. J Bone Miner Res. 2004;19: 133–146.
View Article
Google Scholar

[2] View Article

[3] Google Scholar

[ref2] 2. Lee MH, Reynisdottir I, Massague J. Cloning of p57^KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995;9: 639–649.
View Article
Google Scholar

[5] View Article

[6] Google Scholar

[ref3] 3. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, et al. p57^KIP2, a structurally distinct member of the p21^CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995;9: 650–662.
View Article
Google Scholar

[8] View Article

[9] Google Scholar

[ref4] 4. Hinds P.W., Mittnacht S., Dulic V., Arnold A., Reed S.I., and Weinberg R.A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70: 993–1006. pmid:1388095
View Article
PubMed/NCBI
Google Scholar

[11] View Article

[12] PubMed/NCBI

[13] Google Scholar

[ref5] 5. van der Heuvel S. and Harlow E. Distinct roles for cyclin dependent kinases in cell cycle control. Science, 1993; 26: 2050–2054.
View Article
Google Scholar

[15] View Article

[16] Google Scholar

[ref6] 6. Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, Gorgoulis VG. p57^KIP2: "Kip"ing the cell under control. Mol Cancer Res. 2009;7: 1902–1919.
View Article
Google Scholar

[18] View Article

[19] Google Scholar

[ref7] 7. Borriello A, Caldarelli I, Bencivenga D, Criscuolo M, Cucciolla V, Tramontano A, et al. p57^Kip2 and cancer: time for a critical appraisal. Mol Cancer Res. 2011;9: 1269–1284.
View Article
Google Scholar

[21] View Article

[22] Google Scholar

[ref8] 8. Kavanagh E, Joseph B. The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta. 2011;1816: 50–56. pmid:21447370
View Article
PubMed/NCBI
Google Scholar

[24] View Article

[25] PubMed/NCBI

[26] Google Scholar

[ref9] 9. Jayapal SR, Kaldis P. p57^Kip2 regulates T-cell development and lymphoma. Blood. 2014;123: 3370–3371.
View Article
Google Scholar

[28] View Article

[29] Google Scholar

[ref10] 10. Zhang P, Liégeois NJ, Wong C, Finegold M, Hou H, Thompson JC, et al. Altered cell differentiation and proliferation in mice lacking p57^KIP2 indicates a role in Beckwith–Wiedemann syndrome. Nature. 1997;387: 151–158.
View Article
Google Scholar

[31] View Article

[32] Google Scholar

[ref11] 11. Yan Y, Frisen J, Lee MH, Massague J, Barbacid M. Ablation of the CDK inhibitor p57^Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997;11: 973–983.
View Article
Google Scholar

[34] View Article

[35] Google Scholar

[ref12] 12. Takahashi K, Nakayama K, Nakayama K. Mice lacking a CDK inhibitor, p57^Kip2, exhibit skeletal abnormalities and growth retardation. J Biochem. 2000;127: 73–83.
View Article
Google Scholar

[37] View Article

[38] Google Scholar

[ref13] 13. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Investig. 1979;64: 729–736. pmid:468987
View Article
PubMed/NCBI
Google Scholar

[40] View Article

[41] PubMed/NCBI

[42] Google Scholar

[ref14] 14. Lian JB, Stein GS. Transcriptional control of vitamin D-regulated proteins. J Cell Biochem. 1992;49: 37–45. pmid:1644852
View Article
PubMed/NCBI
Google Scholar

[44] View Article

[45] PubMed/NCBI

[46] Google Scholar

[ref15] 15. Kato S, Suzawa M, Takada I, Takeyama K, Yanagizawa J, Fujiki R, et al. The function of nuclear receptors in bone tissues. J Bone Miner Metab. 2003;21: 323–336. pmid:14586788
View Article
PubMed/NCBI
Google Scholar

[48] View Article

[49] PubMed/NCBI

[50] Google Scholar

[ref16] 16. Suda T, Ueno Y, Fujii K, Shinki T. Vitamin D and bone. J Cell Biochem. 2003;88: 259–266. pmid:12520524
View Article
PubMed/NCBI
Google Scholar

[52] View Article

[53] PubMed/NCBI

[54] Google Scholar

[ref17] 17. Meyer MB, Benkusky NA, Lee C-H, Pike JW. Genomic determinants of gene regulation by 1,25-dihydroxyvitamin D₃ during osteoblast-lineage cell differentiation. J Biol Chem. 2014;289: 19539–19554.
View Article
Google Scholar

[56] View Article

[57] Google Scholar

[ref18] 18. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol. 1997;154: S57–SS73. pmid:9379138
View Article
PubMed/NCBI
Google Scholar

[59] View Article

[60] PubMed/NCBI

[61] Google Scholar

[ref19] 19. Noda M, Vogel RL, Craig AM, Prahl J, DeLuca HF, Denhardt DT. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D₃ receptor and 1,25-dihydroxyvitamin D₃ enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proc Natl Acad Sci U S A. 1990;87: 9995–9999.
View Article
Google Scholar

[63] View Article

[64] Google Scholar

[ref20] 20. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95: 3597–3602. pmid:9520411
View Article
PubMed/NCBI
Google Scholar

[66] View Article

[67] PubMed/NCBI

[68] Google Scholar

[ref21] 21. McKee MD, Nanci A. Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. Connect Tissue Res. 1996;35: 197–205. pmid:9084658
View Article
PubMed/NCBI
Google Scholar

[70] View Article

[71] PubMed/NCBI

[72] Google Scholar

[ref22] 22. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000; 151: 311–320. pmid:11038178
View Article
PubMed/NCBI
Google Scholar

[74] View Article

[75] PubMed/NCBI

[76] Google Scholar

[ref23] 23. Urano T, Narusawa K, Shiraki M, Usui T, Sasaki N, Hosoi T, et al. Association of a single nucleotide polymorphism in the WISP1 gene with spinal osteoarthritis in postmenopausal Japanese women. J Bone Miner Metab. 2007;25: 253–258. pmid:17593496
View Article
PubMed/NCBI
Google Scholar

[78] View Article

[79] PubMed/NCBI

[80] Google Scholar

[ref24] 24. Urano T, Usui T, Takeda S, Ikeda K, Okada A, Ishida Y, et al. TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase. Biochem Biophys Res Commun. 2009;383: 263–268. pmid:19358823
View Article
PubMed/NCBI
Google Scholar

[82] View Article

[83] PubMed/NCBI

[84] Google Scholar

[ref25] 25. Urano T, Shiraki M, Yagi H, Ito M, Sasaki N, Sato M, et al. GPR98/Gpr98 gene is involved in the regulation of human and mouse bone mineral density. J Clin Endocrinol Metab 2012; 97: E565–574. pmid:22419726
View Article
PubMed/NCBI
Google Scholar

[86] View Article

[87] PubMed/NCBI

[88] Google Scholar

[ref26] 26. Hofbauer LC, Heufelder AE. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur J Endocrinol. 1998;139: 152–154. pmid:9724069
View Article
PubMed/NCBI
Google Scholar

[90] View Article

[91] PubMed/NCBI

[92] Google Scholar

[ref27] 27. Koszewski NJ, Reinhardt TA, Horst RL. Vitamin D receptor interactions with the murine osteopontin response element. J Steroid Biochem Mol Biol. 1996;59: 377–388. pmid:9010343
View Article
PubMed/NCBI
Google Scholar

[94] View Article

[95] PubMed/NCBI

[96] Google Scholar

[ref28] 28. Staal A, van Wijnen AJ, Birkenhäger JC, Pols HA, Prahl J, DeLuca H, et al. Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol. 1996;10: 1444–1456. pmid:8923469
View Article
PubMed/NCBI
Google Scholar

[98] View Article

[99] PubMed/NCBI

[100] Google Scholar

[ref29] 29. Urano T, Hosoi T, Shiraki M, Toyoshima H, Ouchi Y, Inoue S. Possible involvement of the p57^Kip2 gene in bone metabolism. Biochem Biophys Res Commun. 2000;269: 422–426.
View Article
Google Scholar

[102] View Article

[103] Google Scholar

[ref30] 30. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R. Vitamin D₃ supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem. 2003;89: 771–777.
View Article
Google Scholar

[105] View Article

[106] Google Scholar

[ref31] 31. Kitazawa R, Kitazawa S, Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim Biophys Acta. 1999;1445: 134–141. pmid:10209265
View Article
PubMed/NCBI
Google Scholar

[108] View Article

[109] PubMed/NCBI

[110] Google Scholar

[ref32] 32. Kitazawa R, Kitazawa S. Vitamin D₃ augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun. 2002;290: 650–655.
View Article
Google Scholar

[112] View Article

[113] Google Scholar

[ref33] 33. Thomas GP, Baker SU, Eisman JA, Gardiner EM. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol. 2001;170: 451–460. pmid:11479141
View Article
PubMed/NCBI
Google Scholar

[115] View Article

[116] PubMed/NCBI

[117] Google Scholar

[ref34] 34. Urano T, Yashiroda H, Muraoka M, Tanaka K, Hosoi T, Inoue S, et al. p57^Kip2 is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor β1. J Biol Chem. 1999;274: 12197–12200.
View Article
Google Scholar

[119] View Article

[120] Google Scholar

[ref35] 35. Nishimori S, Tanaka Y, Chiba T, Fujii M, Imamura T, Miyazono K, et al. Smad-mediated transcription is required for transforming growth factor-β1-induced p57^Kip2 proteolysis in osteoblastic cells. J Biol Chem. 2001;276: 10700–10705.
View Article
Google Scholar

[122] View Article

[123] Google Scholar

[ref36] 36. Kim M, Nakamoto T, Nishimori S, Tanaka K, Chiba T. A new ubiquitin ligase involved in p57^KIP2 proteolysis regulates osteoblast cell differentiation. EMBO Rep. 2008;9: 878–884.
View Article
Google Scholar

[125] View Article

[126] Google Scholar

[ref37] 37. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, et al. Degradation of p57^Kip2 mediated by SCF^Skp2-dependent ubiquitylation. Proc Natl Acad Sci U S A. 2003;100: 10231–10236.
View Article
Google Scholar

[128] View Article

[129] Google Scholar

[ref38] 38. Valcheva P, Cardus A, Panizo S, Parisi E, Bozic M, Lopez Novoa JM, et al. Lack of vitamin D receptor causes stress-induced premature senescence in vascular smooth muscle cells through enhanced local angiotensin-II signals. Atherosclerosis. 2014;235: 247–255. pmid:24880896
View Article
PubMed/NCBI
Google Scholar

[131] View Article

[132] PubMed/NCBI

[133] Google Scholar

[ref39] 39. Joseph B, Wallén-Mackenzie A, Benoit G, Murata T, Joodmardi E, Okret S, et al. p57(Kip2) cooperates with Nurr1 in developing dopamine cells. Proc Natl Acad Sci U S A. 2003; 100: p15619–15624. pmid:14671317
View Article
PubMed/NCBI
Google Scholar

[135] View Article

[136] PubMed/NCBI

[137] Google Scholar

[ref40] 40. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998;247: 610–615. pmid:9647741
View Article
PubMed/NCBI
Google Scholar

[139] View Article

[140] PubMed/NCBI

[141] Google Scholar

[ref41] 41. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329–1337. pmid:9492069
View Article
PubMed/NCBI
Google Scholar

[143] View Article

[144] PubMed/NCBI

[145] Google Scholar

[ref42] 42. Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K, et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun. 1998;251: 796–801. pmid:9790989
View Article
PubMed/NCBI
Google Scholar

[147] View Article

[148] PubMed/NCBI

[149] Google Scholar

[ref43] 43. Nakamichi Y, Udagawa N, Horibe K, Mizoguchi T, Yamamoto Y, Nakamura T, et al. VDR in Osteoblast-Lineage Cells Primarily Mediates Vitamin D Treatment-Induced Increase in Bone Mass by Suppressing Bone Resorption. J Bone Miner Res. 2017; 32:1297–1308. pmid:28177161
View Article
PubMed/NCBI
Google Scholar

[151] View Article

[152] PubMed/NCBI

[153] Google Scholar

[ref44] 44. Weichhaus M, Segaran P, Renaud A, Geerts D, Connelly L. Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis. Cancer Med. 2014;3: 1112–1125. pmid:24976340
View Article
PubMed/NCBI
Google Scholar

[155] View Article

[156] PubMed/NCBI

[157] Google Scholar

[ref45] 45. Goswami S, Sharma-Walia N. Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer. 2015;15: 935. pmid:26608463
View Article
PubMed/NCBI
Google Scholar

[159] View Article

[160] PubMed/NCBI

[161] Google Scholar

[ref46] 46. Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 2006;66: 3620–3628. pmid:16585187
View Article
PubMed/NCBI
Google Scholar

[163] View Article

[164] PubMed/NCBI

[165] Google Scholar

[ref47] 47. Pettersen I, Bakkelund W, Smedsrød B, Sveinbjørnsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005;25: 3809–3816. pmid:16309167
View Article
PubMed/NCBI
Google Scholar

[167] View Article

[168] PubMed/NCBI

[169] Google Scholar

[ref48] 48. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TEM, Blair JM, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 2005;65: 1710–1718. pmid:15753366
View Article
PubMed/NCBI
Google Scholar

[171] View Article

[172] PubMed/NCBI

[173] Google Scholar

Figures

Abstract

Introduction

Materials and methods

Mice

Histology and immunohistochemistry

Preparation of primary mouse osteoblasts

Immunoblot analysis

Immunoprecipitation for the detection of the endogenous p57Kip2-VDR complex

Immunofluorescence staining.

Nodule mineralization

Quantitative RT-PCR

Constructs and transfection

Statistical analysis

Results

The VD3-dependent interaction between VDR and p57Kip2

p57Kip2 enhances the transcriptional activities of VDR

Effects of the ablation of p57Kip2 in primary cultured osteoblasts

p57-/- osteoblasts exhibit defects in osteoclastogenesis

Discussion

Supporting information

S1 Raw images.

S1 File.

Acknowledgments

References

Immunoprecipitation for the detection of the endogenous p57^Kip2-VDR complex

The VD₃-dependent interaction between VDR and p57^Kip2

p57^Kip2 enhances the transcriptional activities of VDR

Effects of the ablation of p57^Kip2 in primary cultured osteoblasts